← Back to overview

ABBV AbbVie Inc.

Biotechnology · $259.36 +0.95%
EN PL
Price Alert:

Compare

Shows % change over the period so different-priced stocks can be compared fairly.

Technical Indicators

RSI (14)
68.5
Relative Strength Index (RSI): measures how fast and how much the price has moved recently, on a 0-100 scale. Above 70 is often called "overbought" (may be due for a pause or pullback); below 30 is "oversold" (may be due for a bounce). It is not a guarantee either way.
SMA 20 / 50 / 200
217.32 / 183.17 / —
Moving Averages (SMA): the average closing price over the last N days, smoothing out day-to-day noise. When price trades above its moving averages, and shorter averages are above longer ones, it is generally read as a healthier trend.
MACD / Signal
18.95 / 16.26
MACD: compares two moving averages (12-day and 26-day) to gauge momentum. When the MACD line crosses above its signal line, momentum is turning up; crossing below suggests momentum turning down.

Fundamentals

P/E
126.5
Price-to-Earnings ratio: how many dollars investors pay for $1 of the company's annual profit. Higher usually means the market expects faster growth (or the stock is expensive); lower can mean it's cheap — or that growth is expected to slow.
Market Cap
458.24B
Market Capitalization: the total value of all the company's shares — share price × number of shares. A rough measure of company size.
Div Yield
2.67%
Dividend Yield: the annual cash dividend paid to shareholders, as a percentage of the current share price.
52-Week Range
187.62 – 261.64
52-Week Range: the lowest and highest price the stock has traded at over the last year. Where the price sits in this range hints at recent strength or weakness.

Trend Analysis

AbbVie Inc. is trading at $259.36, +0.95% versus the previous close. The price is near its 52-week high — the top of its recent trading range.
RSI is in a neutral range — no strong overbought/oversold signal.
MACD is above its signal line — momentum currently leans positive.
Combine this reading with the fundamentals below before forming a view — no single indicator is a guarantee of what happens next.

Latest News

Claiming Social Security at 62 vs. Building a Dividend Bridge: Which Leaves You Richer at 75?
24/7 Wall St. · 2026-07-25 22:46
AbbVie (ABBV) Could Be 3% Undervalued Following Epcoritamab Trial Setback
Simply Wall St. · 2026-07-25 16:09
Why Wall Street Can't Get Enough of This Dividend King
Motley Fool · 2026-07-25 14:35
Johnson & Johnson Is Becoming A Narrower Company Than You Bought
Trefis · 2026-07-25 14:30
SpaceX Lands With a Thud
Barrons.com · 2026-07-24 22:44
J&J's Innovative Medicine Unit Proves Its Resilience in Q2
Zacks · 2026-07-24 14:35
AbbVie (ABBV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Zacks · 2026-07-24 14:00
Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
GlobeNewswire · 2026-07-23 20:00
Educational information only. Nothing here is investment advice — always do your own research and consider talking to a licensed financial advisor before buying or selling.
Data: Yahoo Finance, refreshed periodically and cached locally.